Radiotherapy and PCV chemotherapy

Phase 3Small molecule

Radiotherapy and PCV chemotherapy is one of 17 small molecule programs targeting Oligodendroglioma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OligodendrogliomaActive, not recruiting

OligodendrogliomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

21 competitors in Oligodendroglioma

#DrugCompanyPhaseTrials

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Ibrance

1 3

Leukine

Sanofi

Phase 2

1 4

Verzenio

Eli Lilly

Phase 2

1 5

Beyfortus

BeiGene

Phase 2

—6

Proleukin

IIovance Biotherapeutics, Inc.

Phase 2

1 7

Avastin

BBio-Thera Solutions

Phase 2

—8

Muromonab-CD3

BBarbara Ann Karmanos Cancer Institute

Phase 2

1 9

Antineoplaston A10

BBurzynski Research Institute

Phase 2

1 10

L19TNF

PPhilogen S.p.A.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 3Recruiting

Oligodendroglioma

NCT04702581

Clinical

Trials by Indication[1]

Oligodendroglioma1 trial

A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery

Recruiting·HHospices Civils de Lyon·Phase 3·NCT04702581·280 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Radiotherapy and PCV chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Radiotherapy and PCV chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Radiotherapy and PCV chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hospices Civils de Lyon company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHospices Civils de Lyon

Radiotherapy and PCV chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Oligodendroglioma1 trial

References

Drug Info

Quick Facts

Related News